

Supplementary table | Original study on low risk breast cancer patients, subset on TMA in the present study and subsets on analyzed proteins

	<i>Original cohort</i>	<i>Cohort on TMA</i>	<i>Missing cohort</i>	<i>Pak1</i>	<i>Missing Pak1</i>	<i>pER^{ser305}</i>	<i>Missing pER^{ser305}</i>	<i>Pak1 + pER^{ser305}</i>	<i>Missing Pak1 + pER^{ser305}</i>
	<i>n(%)</i>	<i>n(%)</i>	<i>n(%)</i>	<i>n(%)</i>	<i>n(%)</i>	<i>n(%)</i>	<i>n(%)</i>	<i>n(%)</i>	<i>n(%)</i>
	1780	912	868	786	126	841	71	746	166
<i>Tumor size</i>									
≤ 20mm	1393 (81)	697 (79)	696 (84)	600 (78)	97 (81)	642 (78)	55 (85)	567 (78)	130 (83)
> 20mm	323 (19)	189 (21)	134 (16)	166 (22)	23 (19)	179 (22)	10 (15)	162 (22)	27 (17)
Unavailable	64	26	38	20	6	20	6	17	9
<i>ER status^a</i>									
Negative	296 (20)	195 (22)	101 (17)	168 (22)	27 (22)	182 (22)	13 (20)	161 (22)	34 (22)
Positive	1183 (80)	689 (78)	494 (83)	596 (78)	93 (78)	636 (78)	53 (80)	565 (78)	124 (78)
Unavailable	301	28	273	22	6	23	5	20	8
<i>Tamoxifen</i>									
Untreated	894 (50)	439 (48)	455 (52)	375 (48)	64 (51)	405 (48)	34 (48)	356 (48)	83 (50)
Treated	886 (50)	473 (52)	413 (48)	411 (52)	62 (49)	436 (52)	37 (52)	390 (52)	83 (50)

^a ER-status cut-off: original cohort >0.05 fmol/mg DNA in cytosol assay, present study cohort >10% and >0.05 fmol/mg when immunohistochemical data was missing.